Kolexia
Cartier Lysian Oncologie radiothérapie
Cartier Lysian
Oncologie radiothérapie
Imag En Coupes Avig Vaucl Site Ste Cat
Avignon, France
52 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la prostate Tumeurs du sein Carcinomes Tumeurs du cerveau Récidive tumorale locale Glioblastome Métastase lymphatique Syndrome POEMS Tumeurs de l'anus

Collaborateurs

Voir plus
Hilgers Werner
Hilgers Werner
Institut Sainte Catherine, Avignon, France
Tourniaire Jean
Tourniaire Jean
Polyclinique Urbain V, Avignon, France
Blah Mehdi
Blah Mehdi
Clinique Rhone Durance, Avignon, France
Wodey Jacques
Wodey Jacques
Clinique Rhone Durance, Avignon, France

Industries

Voir plus
Ipsen
22 collaboration(s)
Dernière en 2023
Janssen
12 collaboration(s)
Dernière en 2023
MSD
11 collaboration(s)
Dernière en 2023
Varian Medical Systems France Sarl
10 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a Single Institution between 2009 and 2020.
Cancers   30 mars 2023
Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.
Clinical and translational radiation oncology   08 mars 2023
DARIUS: A Randomized Non-comparative Phase II Multicentric Trial on Short Term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer
Essai Clinique (Bayer)   01 mars 2023
PRESTO: Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial
Essai Clinique (Unicancer)   15 février 2023
GETUG-AFU 22 Phase II Randomized Trial Evaluating Outcomes of Post-Operative Immediate Salvage Radiation Therapy with or without ADT for Patients with Persistently Elevated PSA Level
A Red Journal Special IssueOligometastasis, Part 2   01 décembre 2022
Prise en charge du cancer de la prostate oligorécidivant après traitement local à but curatif, à l’ère des imageries métaboliques et de la radiothérapie stéréotaxique
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie   01 juin 2021
Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET.
Clinical genitourinary cancer   16 mars 2021
P-341 Capecitabine/mitomycin versus 5-fluorouracil/mitomycin in combination with simultaneous integrated boost-intensity modulated radiation therapy for anal cancer
ESMO 22nd World Congress on Gastrointestinal Cancer, 2020 Virtual - 1 - 4 July 2020   01 juillet 2020
Late Toxicity and Quality of Life from GETUG-AFU 22 Study: A Multicenter Randomized Phase II Trial Comparing Radiotherapy +/- 6 Months of Degarelix as a Salvage Treatment for Patients with Detectable PSA after Radical Prostatectomy
Proceedings of the Amercian Society for Radiation Oncology 61st Annual Meeting   01 septembre 2019
The acute toxicity results of the GETUG-AFU 22 study: A multicenter randomized phase II trial comparing the efficacy of a short hormone therapy in combination with radiotherapy to radiotherapy alone as a salvage treatment for patients with detectable PSA after radical prostatectomy.
2017 Genitourinary Cancers Symposium   29 mars 2017